Testimonials

We have contracted Dr. Jan Praslicka in early 2013 to assist us with the evaluation of our preclinical studies, interpretation of results and review of regulatory documents. Collaboration with Dr. Jan Praslicka was recognized as very positive, highly professional and well-structured with great results.

Roman Sivak

CEO, Axon Neuroscience SE, Slovakia

_______________________________________________________________________________________________________

"As a CEO of Hameln RDS, I hired and appointed Jan in summer 2011 to a position of Vice President for Preclinical Sciences to lead three preclinical departments (CRO) and assume temporary responsibility for the clinical department (bioequivalence studies). He led the transformation efforts in his business areas, created new templates and review process for regulatory documents (study plans, study reports), improved internal processes, reviewed and approved SOPs, and took the communication with our clients to a new level. Clients appreciated his pragmatic and straightforward approach to clear interpretation of study results, to troubleshooting and dealing with difficult tasks and with different opinions. Jan Praslicka is a mature professional with extensive experience in pharmaceutical R&D and I have no hesitation to fully recommend him to everyone who seeks support in drug development activities."

Uwe Risse

CEO Dr. Risse Consulting, (Former CEO Hameln RDS a.s.), Germany

_______________________________________________________________________________________________________

"Dr. Jan Praslicka essentially contributed to the lecture day organization of the 7^th Postgraduate Course Toxicology of the Medical University Vienna, held from April 24^th to April 26^th, 2013. Furthermore, it has been highly appreciated that Dr. Praslicka gave several exceptional lectures on the topic of pharmaceutical toxicology and preclinical study conduct."

Bettina Grasl-Kraupp

Professor, Medical University of Vienna, Austria

_______________________________________________________________________________________________________

"I had a privilege to know Jan during his almost 5-year tenure in my nonclinical Department at Takeda. He came with his Study Director experience from preclinical CROs in Canada and a pharma R&D environment in Abbott Laboratories. He was continuously trained and grew professionally in clinical project teams, regulatory writing and interpretation of challenging study findings. He particularly enjoyed interactions with external partners: company sites overseas (UK, Japan), collaborating pharma companies and CROs. With his rich international background and experience in preclinical and translational stages of drug development, I wish Jan all the best in his consulting career."

Mitch Friedman

Senior Director of Toxicology, Takeda Pharmaceuticals, USA

_______________________________________________________________________________________________________

"I know Jan Praslicka from my years at Takeda in USA where i served as Senior Medical Director and later as Executive Medical Director responsible for metabolic and cardiovascular clinical development. Jan represented the nonclinical department for our projects. He always provided scientifically thorough and timely interpretation of pre clinical data and effective advice on complex preclinical regulatory questions which were critical for clinical study planning and the progress of projects."

Eckhard Leifke

Global Head of Development, Diabetes Division, Sanofi, Germany

_______________________________________________________________________________________________________

"I have worked with Jan during his time at Takeda, Jan was a pleasure to work with. I always found him to be a pleasant, reliable and trustworthy person. The quality of Jan's contributions are consistently of a high standard and always practical and helpful. "

Graham Scott

Senior Director, Clinical Pharmacology, Takeda Pharmaceuticals, UK

_______________________________________________________________________________________________________

"Jan and I worked together between 2001 and 2003 when we were Study Directors at a CRO in Canada and we have kept in close touch since. Through our continued interactions and numerous scientific discussions, I have always found Jan to be a dedicated and well-rounded professional who understands issues and talks to the point and is proactive and pragmatic in problem solving. He has a rich repertoire of experience in both the CRO and pharma/biotech sides of the pre-clinical business."

Will Ruddock

Director of Toxicology, ITR Laboratories Canada Inc., Canada